Email this article Prognostic significance of various 11q23/KMT2A rearrangements in infants with acute lymphoblastic leuekemia
- Authors: Tsaur G.A.1,2,3, Riger T.O.1,2, Popov A.M.4, Kustanovich A.M.5, Olshanskaya Y.V.4, Nasedkina T.V.6, Solodovnikov A.G.2,3, Shorikov E.V.7, Demina A.S.1,2, Plekhanova O.M.1, Nokhrina E.S.1, Verzhbitskaya T.Y.1,2, Streneva O.V.1,2, Makarova O.V.1, Arakaev O.R.1,2, Seveliev L.I.1,2,3, Aleinikova O.V.4,8, Lapotentova E.S.7, Myakova N.V.4, Fominykh V.V.4, Kondratchik K.L.9, Boichenko E.G.10, Ponomareva N.I.11, Karachunskiy A.I.4, Roumiantsev A.G.4, Fechina L.G.12
-
Affiliations:
- Regional Children’s Hospital
- Research Institute of Medical Cell Technologies
- Ural State Medical University of Ministry of Healthcare of the Russian Federation
- Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
- The Sharett Institute of Oncology, Hadassah Medical Center
- Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation Engelhardt Institute of Molecular Biology, Russian Academy of Sciences
- PET-Technology Center of Nuclear Medicine
- Belarussian Research Center for Pediatric Oncology, Hematology and Immunology
- Morozov Children's City Clinical Hospital of the Moscow City Healthcare Department
- City Children’s Hospital №1
- Russian Children’s Clinical Hospital of the N.I. Pirogov Russian National Research Medical University, of Ministry of Healthcare of the Russian Federation
- Regional Children’s Hospital Research Institute of Medical Cell Technologies
- Issue: Vol 20, No 1 (2021)
- Pages: 27-39
- Section: ORIGINAL ARTICLES
- Submitted: 14.04.2021
- Accepted: 14.04.2021
- Published: 14.04.2021
- URL: https://hemoncim.com/jour/article/view/477
- DOI: https://doi.org/10.24287/1726-1708-2021-20-1-27-39
- ID: 477
Cite item
Full Text
Abstract
The purpose of this work was evaluation of prognostic significance of 11q23/KMT2A rearrangements in infants (aged under 365 days) with B-cell precursor acute lymphoblastic leukemia (ALL) enrolled in Russian-Belarus multicenter trial MLLBaby. This study is supported by the Independent Ethics Committee and approved by the Academic Council of the Research Institute of Medical Cell Technologies (Ekaterinburg). Various 11q23/KMT2A rearrangements were revealed in 100 (72%) of 139 patients. Event-free survival (EFS) in the intermediate risk group of MLL-Baby trial was 35.1% (standard error (SE) 6.9%), in the high risk group – 38.3% (SE 7.1%) (p = 0.941). The most unfavorable prognosis had infants with translocation t(9;11)/KMT2A-MLLT3: EFS 18.8% (SE 9.8%), cumulative incidence of relapse (CIR) 75.0% (SE 9.7%). Intermediate results were obtained in patients with translocations t(4;11)/KMT2A-AFF1 and t(11;19)/KMT2A-MLLT1: EFS 36.9% (SE 7,2%) and 32,7% (SE 10.4%), respectively; CIR 46.3% (SE 7.8%) and 50.9% (SE 12.3%). The most favorable treatment outcome was achieved in infants carrying translocation t(10;11)(p12;q23)/KMT2A-MLLT10: EFS 83.3% (SE 15.2%), CIR 0,0%. In the multivariate analysis unfavorable outcome of KMT2A-rearranged infant ALL was associated with initial CNS involvement (p = 0.020), initial white blood cell count higher than 300 × 109 /L (p = 0.028), more than 5% blast cells on day 15 in bone marrow (p = 0.012) and presence of translocation t(11;19)/KMT2A-MLLT1 (p = 0.012).
About the authors
G. A. Tsaur
Regional Children’s Hospital;Research Institute of Medical Cell Technologies;
Ural State Medical University of Ministry of Healthcare of the Russian Federation
Author for correspondence.
Email: tsaur@mail.ru
ORCID iD: 0000-0002-9881-6221
Dr. Med. Sci., Head of the Laboratory of Molecular Biology, Immunophenotyping and Pathomorphology;
a leading researcher at the Laboratory of Cellular Therapy for Oncohematological Diseases;
Associate Professor at the Department of Clinical Laboratory Diagnostics and Bacteriology,
32 S. Deryabinoy St., Ekaterinburg 620149
РоссияT. O. Riger
Regional Children’s Hospital;Research Institute of Medical Cell Technologies
Ekaterinburg
РоссияA. M. Popov
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
ORCID iD: 0000-0002-0889-6986
Moscow
РоссияA. M. Kustanovich
The Sharett Institute of Oncology, Hadassah Medical Center
Jerusalem
ИзраильYu. V. Olshanskaya
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
ORCID iD: 0000-0002-2352-7716
Moscow
РоссияT. V. Nasedkina
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian FederationEngelhardt Institute of Molecular Biology, Russian Academy of Sciences
Moscow
РоссияA. G. Solodovnikov
Research Institute of Medical Cell Technologies;Ural State Medical University of Ministry of Healthcare of the Russian Federation
Ekaterinburg
РоссияE. V. Shorikov
PET-Technology Center of Nuclear Medicine
Ekaterinburg
РоссияA. S. Demina
Regional Children’s Hospital;Research Institute of Medical Cell Technologies
Ekaterinburg
РоссияO. M. Plekhanova
Regional Children’s Hospital
Ekaterinburg
РоссияE. S. Nokhrina
Regional Children’s Hospital
Ekaterinburg
РоссияT. Yu. Verzhbitskaya
Regional Children’s Hospital;Research Institute of Medical Cell Technologies
ORCID iD: 0000-0001-9329-1828
Ekaterinburg
РоссияO. V. Streneva
Regional Children’s Hospital;Research Institute of Medical Cell Technologies
Ekaterinburg
РоссияO. V. Makarova
Regional Children’s Hospital
Ekaterinburg
РоссияO. R. Arakaev
Regional Children’s Hospital;Research Institute of Medical Cell Technologies
Ekaterinburg
РоссияL. I. Seveliev
Regional Children’s Hospital;Research Institute of Medical Cell Technologies;
Ural State Medical University of Ministry of Healthcare of the Russian Federation
ORCID iD: 0000-0002-5180-6560
Ekaterinburg
РоссияO. V. Aleinikova
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation;Belarussian Research Center for Pediatric Oncology, Hematology and Immunology
ORCID iD: 0000-0003-0143-1921
Moscow;
Minsk
БелоруссияE. S. Lapotentova
PET-Technology Center of Nuclear Medicine
Ekaterinburg
БелоруссияN. V. Myakova
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
ORCID iD: 0000-0002-4779-1896
Moscow
РоссияV. V. Fominykh
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
Moscow
РоссияK. L. Kondratchik
Morozov Children's City Clinical Hospital of the Moscow City Healthcare Department
Moscow
РоссияE. G. Boichenko
City Children’s Hospital №1
Saint-Petersburg
РоссияN. I. Ponomareva
Russian Children’s Clinical Hospital of the N.I. Pirogov Russian National Research Medical University, of Ministry of Healthcare of the Russian Federation
Moscow
РоссияA. I. Karachunskiy
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
Moscow
РоссияA. G. Roumiantsev
Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation
ORCID iD: 0000-0002-1643-5960
Moscow
РоссияL. G. Fechina
Regional Children’s HospitalResearch Institute of Medical Cell Technologies
ORCID iD: 0000-0002-1885-3912
Ekaterinburg
РоссияReferences
Supplementary files
